Savara Inc宣布将在Chest 2025大会上再次展示莫拉司汀吸入溶液(Molgramostim)治疗自身免疫性肺泡蛋白沉积症(APAP)患者的三期Impala-2临床试验结果。
Savara Inc宣布将在Chest 2025大会上再次展示莫拉司汀吸入溶液(Molgramostim)治疗自身免疫性肺泡蛋白沉积症(APAP)患者的三期Impala-2临床试验结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.